Skip to main content
. 2022 Sep 19;10(9):1560. doi: 10.3390/vaccines10091560

Figure 8.

Figure 8

Sensitivity analysis excluding one or more studies from the analysis to see how this affected the results. (A) Histopathological regression to CIN ≤ 1 [35,36,37,38,41,42], (B) efficacy for complete resolution [35,36,37,39,41], (C) DNA clearance [35,37,38], (D) HPV-T cell response [35,38,42].